The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•4 May 2026•

1 min read

Vanda Pharmaceuticals Launches NEREUS in U.S. as First New Motion Sickness Drug in 40 Years

Key Facts

1Vanda Pharmaceuticals announced the U.S. commercial availability of NEREUS (tradipitant) for the prevention of motion sickness-induced vomiting in adults.

2This medication marks the first new pharmacologic treatment approved for this condition in more than 40 years.

Vanda Pharmaceuticals has officially announced the U.S. commercial availability of NEREUS (tradipitant), a treatment designed to prevent vomiting induced by motion sickness in adults. This launch marks a significant breakthrough in the pharmaceutical industry as the first new pharmacologic treatment approved for this condition in over 40 years. The company is utilizing a direct-to-consumer ordering platform to streamline access and accelerate market penetration. This strategic move addresses a long-standing gap in the healthcare market for motion sickness therapies. Analysts expect the first-in-class product to drive revenue growth for the small-cap biotech firm. Investors are closely monitoring VNDA stock as the company begins capturing value from this long-awaited medical solution.